Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
October 6, 2015 7:50 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening.
U.S. Preventive Services Task Force Webcast and Conference Call Details
  Date:  Tuesday, Oct. 6, 2015 Time: 9 a.m. ET, 8 a.m. CT... MoreCologuard® Included as Alternative Screening Test under Draft USPSTF Guidelines
October 5, 2015 8:21 PM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for colorectal cancer screening starting at age 50 and continuing until age 75.... More
